Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GP01CR01
- Development stage
- Phase 2
- Lead developer
- Exicure
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GP01CR01 is a controlled-release, fixed-dose combination of the CXCR4 antagonist burixafor and the non-selective beta-blocker propranolol. Developed by GPCR Therapeutics, this therapeutic candidate is designed to target the CXCR4-ADRB2 heteromer, a molecular complex discovered by the company to play a critical role in cancer cell survival, metastasis, and resistance to standard treatments. By simultaneously inhibiting the C-X-C chemokine receptor type 4 (CXCR4) and the beta-2 adrenergic receptor (ADRB2), GP01CR01 aims to disrupt oncogenic signaling more effectively than monotherapy. The drug is currently in IND-enabling development for the treatment of various solid tumors—including breast, lung, and brain cancers—as well as hematologic malignancies.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)CXCR4-ADRB2 (C-X-C chemokine receptor type 4 and Beta-2 adrenergic receptor heteromer)
Beyond the preview
Go deeper on GP01CR01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GP01CR01.